Miguel Escobar

List of Publications by Year
in descending order

22 papers	338 citations	933447 10 h-index	839539 18 g-index
22 all docs	22 docs citations	22 times ranked	350 citing authors

#	Article	IF	Citations
1	Postoperative bleeding complications in patients with hemophilia undergoing major orthopedic surgery: A prospective multicenter observational study. Journal of Thrombosis and Haemostasis, 2022, 20, 857-865.	3.8	14
2	IDELVION: A Comprehensive Review of Clinical Trial and Real-World Data. Journal of Clinical Medicine, 2022, 11, 1071.	2.4	6
3	Recombinant von Willebrand factor prophylaxis in patients with severe von Willebrand disease: phase 3 study results. Blood, 2022, 140, 89-98.	1.4	12
4	Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12) Tj ETQq0 0 0 rgBT /Overlock 10	2.1	7
5	A phase IV, multicentre, openâ€label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures. Haemophilia, 2022, 28, .	2.1	6
6	World federation of hemophilia international hemophilia training fellowship program: 50 years of enhancing global care. Haemophilia, 2022, 28, .	2.1	3
7	Immune tolerance induction with antihaemophilia factor (human) in poor prognosis patients with haemophilia A. Haemophilia, 2021, 27, e393-e397.	2.1	2
8	PERSEPT 3: A phase 3 clinical trial to evaluate the haemostatic efficacy of eptacog beta (recombinant) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 2021, 27, 911-920.	2.1	5
9	The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia, 2021, 27, 921-931.	2.1	7
10	Integrated Hemophilia Patient Care via a National Network of Care Centers in the United States: A Model for Rare Coagulation Disorders. Journal of Blood Medicine, 2021, Volume 12, 897-911.	1.7	21
11	Realâ€world data demonstrate improved bleed control and extended dosing intervals for patients with haemophilia B after switching to recombinant factor IX Fc fusion protein (rFIXFc) for up to 5Âyears. Haemophilia, 2020, 26, 975-983.	2.1	12
12	Optimal trough levels in haemophilia B: Raising expectations. Haemophilia, 2020, 26, e334-e336.	2.1	6
13	Efficacy of EHL N9-GP for on-demand treatment of bleeding episodes in hemophilia B: analysis of pivotal trial data . Journal of Blood Medicine, 2019, Volume 10, 243-250.	1.7	0
14	Onceâ€weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8â€GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial). Haemophilia, 2019, 25, 373-381.	2.1	29
15	Switching patients in the age of long-acting recombinant products?. Expert Review of Hematology, 2019, 12, 1-13.	2.2	14
16	Recommendations on multidisciplinary management of elective surgery in people with haemophilia. Haemophilia, 2018, 24, 693-702.	2.1	60
17	Lowâ€factor consumption for major surgery in haemophilia B with longâ€acting recombinant glyco<scp>PEG</scp>ylated factor <scp>IX</scp>. Haemophilia, 2017, 23, 67-76.	2.1	31
18	Advances in the treatment of inherited coagulation disorders. Haemophilia, 2013, 19, 648-659.	2.1	19

#	Article	IF	Citations
19	Utilization patterns and associated costs of factor assistance programmes among persons with haemophilia: a single institution review. Haemophilia, 2012, 18, e95-e100.	2.1	3
20	Multidisciplinary management of patients with haemophilia with inhibitors undergoing surgery in the United States: perspectives and best practices derived from experienced treatment centres. Haemophilia, 2012, 18, 971-981.	2.1	28
21	Health economics in haemophilia: a review from the clinicianâ€™s perspective. Haemophilia, 2010, 16, 29-34.	2.1	39
22	Treatment on demand -in vivo dose finding studies. Haemophilia, 2003, 9, 360-367.	2.1	14